Literature DB >> 17171690

Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status.

Agnieszka Wozniak1, Raf Sciot, Louis Guillou, Patrick Pauwels, Bartosz Wasag, Michel Stul, Joris Robert Vermeesch, Peter Vandenberghe, Janusz Limon, Maria Debiec-Rychter.   

Abstract

Gastrointestinal stromal tumors (GISTs) comprise a biologically diverse group of neoplasms with respect to activating mutations in either KIT or PDGFRA, histology, anatomical site of origin, and clinical aggressiveness. In this study, we applied the high resolution array-based comparative genomic hybridization (array-CGH) technology to 66 primary GISTs (40 gastric and 26 nongastric, 48 with KIT and 18 with PDGFRA mutations) for identification of novel high-level alterations and for characterization of genotype-related genomic changes. All cases had genomic imbalances with the highest occurrence of 14q (73%), 1p (62%), 22q (59%), 15q (38%), and 13q (29%) losses. Our data indicate that loss of chromosome 14 and/or 22 is an early change in GIST tumorigenesis irrespective of tumor genotype. Furthermore, DNA copy number changes showed a site dependent pattern. These included lower incidence of losses at 14q (87% vs. 35%), and higher frequency of losses at 1p (45% vs. 85%) and 15q (17% vs. 69%) in nongastric versus gastric site (P<0.001 for all). However, in the multivariate analysis with adjustment to tumor risk stratification, only the 14q loss site-dependent pattern of distribution retained its significance. These findings suggest that loss of 14q is a relatively less frequent genetic event in the development of nongastric GISTs, the lack of which is most likely substituted by the accumulation of 1p/15q and other changes. The novel minimal overlapping regions of deletion at 1p (1p36.32-1p35.2, 1p34.1, and 1p22.1-1p21.3), 13q (13q14.11-q14.2 and 13q32.3-q33.1), and 15q23 were delineated, which point to chromosomal regions that may harbor genes relevant to the development of these neoplasms. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171690     DOI: 10.1002/gcc.20408

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  36 in total

1.  Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors.

Authors:  Mara Silva; Isabel Veiga; Franclim R Ribeiro; Joana Vieira; Carla Pinto; Manuela Pinheiro; Bárbara Mesquita; Catarina Santos; Marta Soares; José Dinis; Lúcio Santos; Paula Lopes; Mariana Afonso; Carlos Lopes; Manuel R Teixeira
Journal:  BMC Med       Date:  2010-05-14       Impact factor: 8.775

Review 2.  What is New in Gastrointestinal Stromal Tumor?

Authors:  Inga-Marie Schaefer; Adrián Mariño-Enríquez; Jonathan A Fletcher
Journal:  Adv Anat Pathol       Date:  2017-09       Impact factor: 3.875

3.  [Gastrointestinal stromal tumors of the stomach and precursor lesions].

Authors:  E Wardelmann; W Hartmann; M Trautmann; J Sperveslage; S Elges; E Hekeler; S Huss
Journal:  Pathologe       Date:  2017-03       Impact factor: 1.011

4.  A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.

Authors:  Giuseppe Floris; Agnieszka Wozniak; Raf Sciot; Haifu Li; Lori Friedman; Thomas Van Looy; Jasmien Wellens; Peter Vermaelen; Christophe M Deroose; Jonathan A Fletcher; Maria Debiec-Rychter; Patrick Schöffski
Journal:  Clin Cancer Res       Date:  2012-12-11       Impact factor: 12.531

Review 5.  Molecular characterization and pathogenesis of gastrointestinal stromal tumor.

Authors:  Takeshi Niinuma; Hiromu Suzuki; Tamotsu Sugai
Journal:  Transl Gastroenterol Hepatol       Date:  2018-01-09

Review 6.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

7.  Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors.

Authors:  Yuzhi Pang; Feifei Xie; Hui Cao; Chunmeng Wang; Meijun Zhu; Xiaoxiao Liu; Xiaojing Lu; Tao Huang; Yanying Shen; Ke Li; Xiaona Jia; Zhang Li; Xufen Zheng; Simin Wang; Yi He; Linhui Wang; Jonathan A Fletcher; Yuexiang Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

Review 8.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 9.  Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.

Authors:  Piotr Rutkowski; Maria Debiec-Rychter; Wlodzimierz Ruka
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

10.  CGHnormaliter: an iterative strategy to enhance normalization of array CGH data with imbalanced aberrations.

Authors:  Bart P P van Houte; Thomas W Binsl; Hannes Hettling; Walter Pirovano; Jaap Heringa
Journal:  BMC Genomics       Date:  2009-08-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.